Invention Description

​
The NeuroPrecision tool provides a prognostic biomarker that can predict a patient’s response to antipsychotic medications based on data extracted from a resting state functional MRI scan. The algorithm reports whether the patient is likely to be a responder or non-responder to standard antipsychotic treatment. This clinical decision support tool may be leveraged to drive improved patient care and enhance clinical trial designs for novel therapies.

about

Applications

Clinical trial design and patient selection:

(1) Identify relevant patient sub-groups (predicted responder vs non-responder) for targeted treatment

(2) Determine efficacy of novel agent vs. predicted response to conventional treatment

Patient care planning:

(1) Prepare patients and families for treatment outlook based on response prediction 

(2) Expedite aggressive treatment options for predicted non-responders 

(3) Predict potential expenses and minimize duration of hospitalization

NEUROPRECISION

Intellectual Property

US Provisional Patent Application 62/085,707